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Abstract  
 
Pulmonary arterial hypertension (PAH) describes a group of conditions with a common 
hemodynamic phenotype of increased pulmonary artery pressure, driven by progressive 
remodeling of small pulmonary arteries, leading to right heart failure and death. 
Vascular remodeling is the key pathological feature of PAH but treatments targeting this 
process are lacking. In this review, we summarize important advances in our 
understanding of PAH pathogenesis from genetic and epigenetic factors, to cell 
metabolism and DNA damage. We show how these processes may integrate and 
highlight exploitable targets that could alter the relentless vascular remodeling in PAH.   
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Pulmonary Vascular Remodeling in PAH ± Many Problems, Few Solutions. 
Pulmonary hypertension (PH) is defined by a mean pulmonary artery pressure of 
greater than 25 mmHg at rest [1]. Diagnostic groups are further classified according to 
clinical, etiological and hemodynamic features (Table 1) but share common symptoms 
of increased breathlessness on exertion, right heart failure and ultimately result in 
premature death [1]. Pulmonary arterial hypertension (PAH) (see Glossary) is 
characterized by sustained vasoconstriction and a progressive obliteration of small 
resistance pulmonary arteries and arterioles through a process of intimal and medial 
thickening and the formation of angioproliferative plexiform lesions [2]. Pulmonary 
vascular insults cause endothelial dysfunction and apoptosis thereby impairing 
endothelial-mediated suppression of quiescent smooth muscle cells [3]. This, coupled 
with clonal expansion of apoptosis-resistant endothelial cells, promotes a proliferative 
vasculopathy that also involves a complex interplay with adventitial fibroblasts, 
perivascular inflammatory cells and the extracellular matrix [3]. Despite considerable 
advances in PAH treatment, this devastating disease still carries a prognosis worse 
than many cancers with a 3-year survival of 68-70% [4, 5]. Current therapies 
predominantly target pulmonary vasoconstriction rather than proliferative vascular 
remodeling and therefore new strategies are urgently required to directly address the 
pathological remodeling that underpins the disease. 
 
PAH constitutes diagnostic Group 1 (Table 1) and is characterized by added 
hemodynamic criteria that define pre-capillary pulmonary hypertension with absence 
of left-sided heart disease (Group 2), lung diseases (Group 3) or thromboembolic 
disease (Group 4). However, Group 1 comprises patients with a wide range of 
conditions that are associated with the development of PAH and thus within this group, 
there may be considerable mechanistic heterogeneity at a molecular and 
pathophysiological level. Consequently, we limit this review by focusing on key 
pathogenic processes of idiopathic PAH (IPAH) and its heritable form (HPAH), rare 
conditions with a combined annual incidence of approximately 1-2 per million [4, 6].  
 
The breadth of disruption of pulmonary vascular cell biology in PAH is becoming 
apparent.  Recent studies of genetic and epigenetic factors, DNA damage and 
disordered metabolism have yielded important mechanistic insights into established 
disturbances of endothelial function and smooth muscle cell proliferation. We discuss 
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the central importance of bone morphogenetic protein receptor 2 (BMPR-II) signaling 
in PAH and focus on approaches to rescue the disease-associated suppression of this 
pathway. Other new genetic leads are explored and the rapidly expanding field of 
microRNA biology and its relevance to PAH is discussed. Furthermore, work on triggers 
for PAH development has added to our understanding of the role of inflammation and 
hypoxia in PAH and we highlight key recent findings in these areas.  Although it is not 
yet clear how all of these problems combine temporally and mechanistically, these 
advances bring enormous potential for new therapeutic approaches that specifically 
target vascular remodeling, providing fresh hope of significant impact on disease 
progression and improved patient outcomes.   
 
The Ups and Downs of BMPR-II Signaling in PAH. 
Since the identification of mutations in the gene encoding bone morphogenetic protein 
receptor 2 (BMPR2) in families with PAH [7, 8], BMPR2 has become the predominant 
genetic factor in heritable forms of the disease, with a large amount of evidence 
implicating it as a central molecular player in PAH. BMPR-II is a member of the 
transforming growth factor beta (TGF-E) receptor family that forms a dimer with an 
activin receptor-like kinase (ALK) [9].  There are multiple ALKs and each heterodimeric 
combination confers different ligand affinity [10].  Thus, differential expression in tissues 
may alter sensitivity to specific bone morphogenetic protein (BMP) ligands.  Notably, the 
BMPR-II/ALK-1 heterodimer signals with relative specificity in response to BMP9 and 
BMP10 in human microvascular endothelial cells (ECs) [11] while BMPR-II/ALK-3 or -6 
signals in response to BMP2 or BMP4 in smooth muscle cells [12]. Upon ligand binding, 
the receptor phosphorylates SMAD proteins (mothers against decapentaplegic 
homologs) that complex and translocate to the nucleus, regulating in turn the 
expression of target genes (e.g. inhibitor of DNA binding (ID) proteins) through SMAD 
binding elements (Figure 1) [13]. 
Mutations in BMPR2 have been found in >70% of patients with heritable disease [7, 8] 
and in up to 25% of patients with idiopathic disease [14].  On the one hand, reduced 
protein expression of BMPR-II is also found in patients with PAH devoid of BMPR2 
mutations [15], emphasizing the importance of this signaling pathway in disease.  But 
on the other hand, in HPAH, while transmission is autosomal dominant, only 20% of 
carriers develop disease, implying that other triggers are required [16].   The importance 
of environmental or host factors (Figure 2) in addition to impaired BMPR-II signaling is 
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supported by evidence from BMPR-II-deficient animal models. For instance, mice with 
heterozygous null or hypomorphic Bmpr2 mutations do not develop spontaneous PAH, 
and only around 30% of mice with either Cre-dependent deletion of Bmpr2 in ECs [17] 
or inducible overexpression of a dominant negative BMPR-II in smooth muscle cells [18] 
show evidence of elevated right ventricular systolic pressure (RVSP). In contrast, a 
more recent study used mice incorporating a heterozygous knock-in allele bearing the 
R899X stop mutation in exon 12, a Bmpr2 mutation associated with human PAH, and 
these animals developed spontaneous elevation in RVSP by 6 months of age [19]. In 
this model, penetrance and disease severity were enhanced by additional knockout of 
the Smad1 gene, suggesting that suppression of BMPR-II signaling might be sufficient 
to precipitate disease [19]. However, the explanation for the difference in disease 
susceptibility between mice with haploinsufficiency due to heterozygous null or R899X 
mutations in Bmpr2 remains unclear and warrants further investigation. Interestingly, a 
transgenic rat with a heterozygous 140 base pair deletion in exon 1 of the Bmpr2 gene 
has recently been described [20]. While not yet fully phenotyped, by 3 months of age 
these rats developed abnormal muscularization of small pulmonary arteries compared 
to wild-type littermates, although this was not associated with significant hemodynamic 
changes at that age [20]. These early remodeled vessels showed evidence of 
endothelial-to-mesenchymal (EndoMT) transition, with overexpression of relevant 
markers (such as Twist-1 and phosphorylated vimentin) by immunohistochemistry [20]. 
Evidence of EndoMT was also observed by staining human PAH lung sections and 
sections from monocrotaline-treated rats [20]. Another study demonstrated that siRNA 
knockdown of BMPR2 induced mesenchymal phenotypic changes in human pulmonary 
artery endothelial cells (PAECs) [21]. This was associated with increased expression of 
high mobility group AT-hook 1 (HMGA1) and Slug, transcription factors that have 
been implicated in epithelial-to-mesenchymal transition and are overexpressed in 
PAECs from patients with BMPR2 mutations [21]. 
BMPR-II deficiency also impacts upon mechanisms involved in the reversal of vascular 
remodeling.  In the knowledge that hypoxia-induced pulmonary hypertension in mice 
is ubiquitously reversible, one study demonstrated that EC-specific deletion of Bmpr2 
inhibited reversal of PH upon reoxygenation [22].  Mitochondrial dysfunction in BMPR-II 
deficient endothelial cells led to mitochondrial DNA damage and apoptosis, preventing 
regeneration of distal pulmonary arteries following hypoxia/reoxygenation [22]. 
Importantly, the sensitivity of PAECs to mitochondrial-induced apoptosis with 
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hypoxia/reoxygenation was confirmed in vitro in primary cells from patients with BMPR2 
mutations [22]. While broader abnormalities in cellular metabolism -- including aerobic 
glycolysis, pentose phosphate pathway activation and abnormal fatty acid metabolism -- 
have been reported in PAH (Box 1), this finding of mitochondrial dysfunction in BMPR-
II-deficient cells implies that genetic predisposition directly alters the capacity to repair a 
pulmonary vascular injury. Moreover, as will be discussed later, impaired BMPR-II 
signaling predisposes to pro-inflammatory phenotypes in pulmonary vascular tissue 
cells that may exacerbate the injury response and promote disease progression [22].  
While targeting EndoMT, mitochondrial dysfunction and inflammation may be possible, 
the pleotropic effects of suppressed BMPR-II signaling in PAH stress the importance of 
restoring this pathway as a therapeutic objective.  
 
The Sexy Side of BMPR-II. 
An important host factor associated with disease susceptibility is sex, with a female to 
male ratio of approximately 2.5:1 in recent IPAH cohorts. [4, 6]. The mechanisms 
underlying this predisposition are becoming clearer and link closely to BMPR-II 
signaling.  For example, estrogen has been shown to suppress BMPR-II signaling [23] 
with sex-specific consequences for in vitro PASMC phenotypes [24]. Female, but not 
male human PASMCs, proliferate in response to the same dose of key mitogens (e.g. 
serotonin (5HT), platelet-derived growth factor (PDGF), suggesting heightened 
sensitivity to pro-proliferative stimuli [24].  In this study, sex differences were attributed to 
suppression of SMAD activation upon stimulation, in addition to a reduction in basal 
expression of BMPR-II pathway components including BMPR-II, SMAD1/5/8, and the ID 
proteins, ID1 and ID3 [24]. These in vitro findings are supported by the in vivo 
observation that the aromatase inhibitor anastrazole reduced progression of 
established PAH in female rats and mice [25]. Translation of these pre-clinical studies 
into human trials is eagerly anticipated, particularly in view of recent evidence, from a 
small case-control study, that male patients with PAH exhibit significantly higher levels 
of circulating estradiol when compared to healthy controls [26]. However, there is an 
apparent paradox in these findings, as male sex is a predictor of worse survival in 
patients with PAH, a finding associated with poorer right ventricular function [27, 28]. 
Possible explanations for this include the relative deficiency in male patients of 
dehydroepiandrosterone [26], a precursor of testosterone and estrogen that is protective 
in rodent PH models [29]. Alternatively, these findings could be linked to the differential 
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effects of male and female sex hormone metabolite profiles on the pulmonary 
vasculature and right ventricle (reviewed in [30]).   
 
More BMPR-II ±Amplifying the Signal for Therapeutic Benefit. 
The evidence implicating BMPR-II deficiency in PAH pathogenesis has driven efforts to 
enhance or restore the BMPR-II signaling. Moreover, therapeutic agents targeting this 
mechanism are progressing into human trials (Figure 1). One study performed a high 
throughput screen of FDA-approved drugs using a luciferase reporter assay and 
identified FK506 (tacrolimus) as an activator of BMPR-II signaling [31]. FK506, 
administered via continuous subcutaneous infusion by osmotic pump, prevented the 
development of PAH in mice with endothelial deletion of Bmpr2 and furthermore, 
reversed established PAH in two rat models [31]. Indeed, there are also initial reports 
of positive clinical responses from compassionate use of FK506 in patients with severe 
PAH but these beneficial effects will require verification in ongoing clinical trials [32].  
Other work has demonstrated direct amplification of BMP signaling using the endothelial 
selective ligand, BMP9 [19]. In vitro, BMP9 reduced tumor necrosis factor (TNFD)-
induced EC apoptosis and inhibited endothelial monolayer permeability induced by 
endotoxin in both pulmonary artery ECs, as well as in blood outgrowth ECs  [19]. In 
rodent models, BMP9 reversed the spontaneous development of PAH in mice with 
heterozygous R899X mutations and reversed established PAH in rat models [19]. 
Earlier work from the same group demonstrated that the lysosomal inhibitor chloroquine 
could increase the cell surface expression of BMPR-II in ECs, and could be used as a 
strategy to restore BMP9-BMPR-II signaling in cells with BMPR2 mutations [33]. 
Although EC apoptosis and monolayer permeability are enhanced by BMPR-II 
haploinsufficiency [34], it was notable that the in vitro benefits conferred by BMP9 were 
preserved in cells bearing BMPR2 mutations, implying that reduced signaling can be 
directly augmented by BMP9 without restoration of receptor expression [19]. 
Augmentation of the pathway via suppression of negative regulation is another 
emerging strategy. The downstream effectors of BMPR-II signaling, SMAD proteins, are 
negatively regulated by ubiquitination and proteasomal degradation [35]. Recent 
evidence in rodent models of PAH and in explanted lung tissue from patients with or 
without BMPR2 mutations has demonstrated upregulation of SMURF1, a ubiquitin 
ligase that can target SMAD proteins and BMP receptors, [36, 37]. Indeed, genetic 
deletion of Smurf1 protected mice from the development of experimental PAH while 
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nebulized administration of a micro-RNA (miR-140-5p), shown to target and repress 
SMURF1, attenuated PAH in rat models [36]. As small molecule inhibitors of SMURF1 
are now available, these may potentially offer another mode of enhancing BMPR-II 
signaling [38].  
Finally, a different group described an additional mechanism to restore BMPR-II 
signaling via activation of the transcription factor, Forkhead box O1 (FoxO1) [39]. This 
master-regulator of cellular proliferation was shown to be downregulated in PAH in 
human lungs, a finding that could be replicated through exposure of PASMCs to 
inflammatory cytokines (TNFD, IL-6) and growth factors (PDGF, insulin growth factor 1 
(IGF-1)) ex vivo [39].  Pharmacological inhibition of FoxO1 induced proliferation of 
PASMCs and furthermore, smooth muscle-specific FoxO1 deletion in mice led to a 
spontaneous PH phenotype [39]. Conversely, activation of FoxO1 with the 
chemotherapeutic agent, paclitaxel, suppressed PAH PASMC proliferation and 
reversed in vivo PH models [39]. Although the activation of FoxO1 was associated with 
restoration of BMPR-II signaling in animal models, suppression of in vitro PASMC 
proliferation was not dependent upon an intact BMPR-II pathway, implying that 
paclitaxel might have therapeutic benefits even in the presence of BMPR2 mutations.  
These strategies to target one of the key pathways implicated in PAH pathogenesis 
offer real potential to translate into disease-modifying treatments, even for patients with 
BMPR2 mutations. However, given diversity of the molecular mechanisms involved and 
the limited pool of patients for large randomized trials, work to predict those likely to 
respond to specific strategies should be encouraged.  
 
Beyond BMPR2 ± Other Genetic Regulators of IPAH. 
Analysis of candidate BMP/SMAD pathway genes have revealed rare mutations in PAH 
patients including SMAD1, SMAD4 and SMAD9 (reviewed in [14]). Next generation 
techniques such as whole exome sequencing have identified mutations in other genes 
providing insight into other potentially important regulators of PAH pathogenesis. For 
example, a study of a large family with autosomal dominant HPAH revealed a shared 
mutation in exon 3 of CAV1 [23]. The product of this gene, Caveolin-1, is a structural 
component of specialized plasma membrane microdomains, caveolae, which are critical 
for the maintenance of endothelial function and permeability [40]. Interestingly, 
pulmonary artery ECs from mice with heterozygous null Bmpr2 mutations have caveolar 
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trafficking defects and these have been linked to the impaired barrier function exhibited 
by these cells [41].    
In a further study of HPAH patient exome sequences, Ma et al. identified a coding 
variant in the potassium channel, subfamily K, member 3 (KCNK3) [42]. Expression of 
KCNK3 and its current was subsequently found to fall in rat smooth muscle cells, freshly 
isolated during development of monocrotaline-induced PH, while pharmacological 
inhibition of KCNK3 induced pulmonary vascular cell proliferation in vivo in rats and 
increased right ventricular systolic pressure [43]. By contrast, activation of KCNK3 
attenuated PH development but was unable to reverse the disease, perhaps due to 
disease-mediated reduction in channel expression [43].   
In a study of IPAH patients with no known PAH-linked mutations, candidate genes 
associated with genetic variants were prioritized on the basis of putative relevance to 
pulmonary biology, human disease and known expression in heart and lung tissue [44]. 
This study reported TopBP1 as a candidate gene of interest, given its role in the DNA 
damage response, an emerging area of PAH biology (Box 2). Mutations in this gene 
may contribute to disease penetrance in BMPR2 mutation carriers or alter disease 
susceptibility in the context of environmental triggers (Figure 2).   
Given the rarity of IPAH, genome-wide association studies have been limited by 
insufficient sample sizes. To improve power, one study employed a case-control 
approach in two independent cohorts of patients without detectable BMPR2 mutations 
and identified two polymorphisms downstream of the CBLN2 gene that were associated 
with IPAH [45]  How the protein product, Cerebellin-2, contributes to PAH pathogenesis 
remains unclear, but may involve inhibition of PASMC proliferation [45]. 
While there is huge potential to discover rare genetic variations associated with PAH 
through the analysis of coding sequences, and now, whole genome sequencing with 
next generation sequencing, interpretation of these data remains difficult.  Indeed, large 
patient numbers are required to identify rare causal variants with sufficient power. The 
successful use of these technologies in this rare disease will therefore require broad 
international collaborations. 
 
The Role of microRNAs in PAH.  
Beyond the genetic factors involved in PAH, a broad disruption of transcriptional 
regulation is now also evident. The expression of numerous micro-RNAs (miRs) is 
altered in the circulation and lung tissue of patients with PAH [36, 46, 47] and, as 
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mentioned, miRs can affect BMPR-II signaling [36] and DNA repair mechanisms in PAH 
(Box 2) [48]. 
Most studies have focused on individual miRs and cell-specific responses in PAH. 
However, an elegant study using a network-based bioinformatics approach has shown 
evidence of a coordinated regulation of miR biology in PAH [49].  This study identified 
members of the miR-130/301 family, as key regulators of other miRs and consequent 
cell phenotypes in PAH [49]. The authors proposed that miR-130/301 represses 
peroxisome proliferator±activated receptor-J (PPARJ), a target of BMP signaling 
[50], and confirmed this in vitro by forced expression of miR-130a in human ECs and 
PASMCs [49]. PPARJ might in turn regulate both a STAT3-miR-204-SRC pathway 
implicated in PASMC proliferation and apoptosis resistance [51] and an apelin-miR-
424/503-FGF2 pathway, to maintain PAEC homeostasis and suppress PASMC 
proliferation [52]. Moreover, upregulation of the miR-130/301 family was demonstrated 
in rodent models and lung sections and plasma from patients with PAH [49]. In addition, 
factors capable of inducing its upregulation in vitro included hypoxia and inflammatory 
cytokines (IL-1E and IL-6), known triggers or drivers of PAH.   
The explosion in miR biology opens many potential therapeutic avenues and a variety of 
miR mimics or inhibitors have shown efficacy in animal PAH models (Table 2).  
However, target specificity, cellular penetration, degradation and possible hepatotoxicity 
represent significant hurdles that need to be overcome for these molecules to translate 
into therapeutic interventions in humans.  
 
Disease Drivers in PAH.  
While the described disturbances in BMPR-II pathway regulation, metabolism and DNA 
damage/repair mechanisms are fundamental in PAH pathophysiology, the triggers and 
drivers of disease (both in the presence and absence of genetic predisposition) remain 
unclear. Recent studies have provided insight into the involvement of hypoxia and 
inflammation as potential environmental mediators or drivers of PAH.  
 
Hypoxic Signals Triggering PAH. 
Ambient hypoxia is widely used as a stimulus for a proliferative vasculopathy in animal 
PH models; it also triggers reversible pulmonary vascular remodeling in humans 
following ascent to high altitude [53, 54].  Alveolar hypoxia is likely to be an integral 
pathogenic factor in Group 3 patients (Table 1) but relative pulmonary arterial hypoxia 
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due to progressive mixed venous hypoxemia in IPAH may also be an important driver 
of this disease.  Cellular oxygen-sensing is multi-layered and tissue-specific but the 
hypoxia-inducible transcription factors, HIF-1D and HIF-2D, are key regulators of 
hypoxic adaptation in pulmonary vascular cells (reviewed in [55]). Expression of HIF-Į 
subunits is tightly controlled by oxygen-sensitive prolyl hydroxylase domain-
containing enzymes (PHDs) which, in the presence of oxygen, hydroxylate and target 
HIF-Į VXEXQLWV IRU XELTXLWLQDWLRQ by the von-Hippel Lindau protein (VHL) and 
proteasomal destruction [56]. It has long been known that heterozygosity of either Hif1a 
[57] or Hif2a [58] protects mice from hypoxia-induced PH but the mechanism has been 
unclear. The dominant regulation of metabolic genes by HIF-1D is likely to be important 
given the metabolic changes favoring aerobic glycolysis in pulmonary vascular cells 
(Box 2) and normoxic stabilization of HIF-1D has been described in human pulmonary 
vascular lesions [59]. However, recent evidence has highlighted the importance of 
endothelial HIF-2D in animal models of PH.  
One study reported that mice harboring a Phd2 (Egln1) deletion in endothelial and 
hematopoietic cells (Tie2-Cre expression) developed a spontaneous and fatal PH 
phenotype with impressive pulmonary vascular remodeling and hemodynamic changes 
[60]. As expected, both HIF-D isoforms were upregulated in normoxic PHD-2 deficient 
ECs, but double knockout studies (Phd2 and Hif1a or Hif2a) indicated HIF-2D was the 
key mediator of the phenotype [60]. Several pathways implicated in PH were altered in 
PHD-2 deficient mice including downregulation of Bmpr2 and Cav1 and could be 
rescued by deletion of Hif2a [60]. The proposed mechanism involved HIF-2D-mediated 
upregulation of chemokine CXCL12, a proliferative stimulus for PASMCs. Similar 
findings were independently obtained using an alternative mouse line (Cdh5-Cre 
expression) to conditionally delete Phd2; however, this paper focused on hypoxic 
induction of the vasoconstrictor endothelin-1 (Edn1) as a potential mechanism, showing 
HIF-2D-dependent increases in lung expression of Edn1 in PHD-2 deficient mice  [61].  
Interestingly, PAH has also been described in humans with rare gain-of-function 
mutations in HIF2A [62]. However, PAH was not reported as a cause of death in a small 
study of patients with HIF activation due to mutations in the VHL gene (Chuvash 
polycythemia) [63], even though such patients do present heightened pulmonary 
vasoconstriction in response to hypoxia [64].  
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There are several alternative mechanisms for the regulation of PAH by HIF-2D. It has 
been recently demonstrated that the protection against hypoxia-induced PH mediated 
by EC deletion of Hif2a in mice is associated with reduced expression of arginases and 
that deletion of endothelial Arg1 reproduced a protective phenotype [65]. Moreover, the 
endothelial NO pathway is strongly implicated in PAH and may represent an important 
therapeutic target [66]. Thus, diversion of L-arginine from nitric oxide synthase through 
increased arginase activity may be a credible disease driver. Notably, a further target of 
HIF-2D is the transcription factor, POU5F1 (or OCT4), which can upregulate miR-
130/301 in ECs and PASMCs exposed to hypoxia, as discussed earlier [49]. Finally, 
through elegant linkage analysis and congenic breeding of a rat strain known to be 
resistant to hypoxia-induced PH (the Fisher 344 strain), the Slc39a12 gene was 
identified as a novel HIF-activated regulator of hypoxia-induced pulmonary vascular 
remodeling [67]. The upregulation of the protein product, zinc transporter (ZIP12), in 
hypoxic pulmonary vascular tissue was conserved across several species and 
confirmed in IPAH tissue, while mutation of Slc39a12 attenuated hypoxia-induced 
pulmonary hypertension in rats [67]. In light of these multiple strands of evidence for 
HIF-pathway activation in PAH, it may be important to consider screening for PH in 
patients treated with PHD inhibitors (e.g. Roxadustat), which are progressing in clinical 
trials to ameliorate renal anemia [68]. 
 
 
 
Inflammation and Cytokines ± Potential Targets in PAH.  
Perivascular inflammation is a characteristic feature of PAH [2] and many inflammatory 
cell-types are mooted to have roles in disease pathogenesis [19, 69].  Elevated 
inflammatory cytokine levels are described in IPAH patients [70, 71] but whether 
inflammation is a trigger for disease in susceptible patients or a consequence of 
established disease is not clear. There is increasing evidence that genetic 
predisposition to PAH through BMPR-II deficiency involves a pro-inflammatory 
phenotype. Human PAECs transfected with BMPR2 siRNA exhibited enhanced 
expression of IL-6 and IL-8 compared to control cells [22] and BMPR2+/- human 
PASMCs released more IL-6 in response to endotoxin (LPS) [72]. BMPR-II deficient 
mice showed increased expression of IL-6 and KC (murine IL-8) in lung tissue in 
response to LPS and these findings were mirrored in murine PASMCs ex vivo [72]. Of 
note, murine PASMCs were isolated from haploinsufficient BMPR-II mice with no 
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evidence of PH but exposure of such mice to LPS for 6 weeks was sufficient to induce 
disease supporting the hypothesis that inflammation plays an initiating role in PAH, at 
least in the context of BMPR-II deficiency [72]. BMPR-II deficient human and murine 
PASMCs and Bmpr2 haploinsufficient mouse lungs demonstrated superoxide 
dismutase (SOD3) deficiency, implicating impaired handling of reactive oxygen species 
in the mechanism underlying the pro-inflammatory phenotype in these models [72]. 
Indeed, both in vitro inflammatory responses due to BMPR-II deficiency and the 
development of PH in BMPR-II deficient mice following chronic LPS exposure could be 
attenuated by tempol, an antioxidant [72].  These data imply that antioxidant 
supplementation and targeting specific cytokines (e.g. IL-6) might represent strategies 
to prevent the development of PAH in patients with BMPR2 mutations.  
How BMPR-II regulates increased inflammatory cytokine expression is not fully 
understood but recent work has implicated the eukaryotic translation initiation factor 
(eIF2) as a translational regulator of TNF-induced granulocyte macrophage colony-
stimulating factor (GM-CSF) release from human PAECs [73]. In this study, BMPR-II 
deficiency was associated with sustained activation of p38 mitogen-activated protein 
kinase (MAPK) following TNF stimulation which indirectly led to de-phosphorylation of 
eIF2 and thus, enhanced GM-CSF translation [73].  In human IPAH there was evidence 
of higher GM-CSF expression in diseased lung tissue, while administration of GM-CSF 
in mice worsened PH in chronic hypoxia, consistent with a role for this cytokine in 
disease progression [73]. The importance of wider translational repression by eIF2 
deserves exploration given the observation that mutations in this pathway -- specifically 
loss-of-function homozygous and compound heterozygous mutations in EIF2AK4, the 
gene encoding eIF2D kinase 4 -- have been documented in other conditions of aberrant 
pulmonary vascular remodeling such as pulmonary veno-occlusive disease and 
pulmonary capillary hemangiomatosis [74, 75].   
Associated with the enhanced GM-CSF signaling described above, an increase in 
perivascular cells expressing macrophage markers was reported [73] suggesting that 
macrophage-derived cytokines such as leukotriene B4 [76] and IL-6 [70, 77] may be 
implicated in PAH. Given the potential for biological targeting of specific cytokines that 
may be pathogenically over-expressed in PAH, the role of macrophage and tissue-
derived cytokines in vascular remodeling is of particular interest.  
Our group explored the role of TNF±related apoptosis-inducing ligand (TRAIL) in PAH, 
a TNF family member. Expression of TRAIL was upregulated in lung tissues from rodent 
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models of PH [78], in human lung sections and in PASMCs isolated from PAH patients 
[79]. Despite its known role of inducing apoptosis in transformed or malignant cells 
TRAIL acted as a PASMC mitogen in vitro [80]. Furthermore, blockade of TRAIL by 
either genetic deletion in mice or by administration of an anti-TRAIL polyclonal antibody 
in rats, prevented development of PH [80]. Moreover, polyclonal antibody targeting of 
TRAIL reversed established disease in mouse PH models [80].  Of note, 
osteoprotegerin (OPG), a binding partner for TRAIL -- best known for its role in bone 
formation -- is similarly of mechanistic and therapeutic interest [78]. In fact, levels of 
OPG are also increased by suppressed BMPR-II, serotonin and inflammatory stimuli 
(e.g. IL-1) [79], and serum levels correlated with markers of disease severity (right atrial 
pressure and cardiac index) and predicted survival in PAH patients [81]. In addition, 
OPG, like TRAIL, drives proliferation of human PASMCs in vitro [79, 80]. Thus, studies 
investigating the therapeutic potential of targeting OPG in rodent models are currently 
underway [82]. 
 
 
 
Concluding Remarks  
Recent advances have revealed a wide range of biological disruption in PAH including 
metabolic, inflammatory and epigenetic abnormalities (Figure 2, Box 3). Understanding 
how all these processes integrate to promote the aberrant proliferative remodeling 
characteristic of PAH will be key to the generation of successful anti-remodeling 
therapies. Other questions also remain (see Outstanding questions), in particular how 
best to increase the success rate of translating pre-clinical discoveries to the bedside, 
which has been a significant challenge in PH [83].  It is noteworthy that the majority of 
studies in this review highlighting new therapeutic targets have incorporated both in vitro 
evidence from patient cells and often more than one animal model of disease, hopefully 
strengthening the translational potential of these discoveries.  
Clear hubs for new therapies to target certainly exist.  As highlighted above, novel 
strategies to enhance BMPR-II signaling (Figure 1) may be among the first of a new 
generation of drugs for PAH that specifically target known defective molecular 
regulators of pulmonary vascular remodeling. In addition, our increased understanding 
of metabolic abnormalities and inflammation has led to clinical trials targeting the 
metabolic switch to a pro-proliferative glycolytic phenotype in pulmonary vascular cells 
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(e.g. Dichloroacetate, NCT01083524) and pro-proliferative cytokine pathways (e.g. 
anti-IL-6 antibody, Tocilizumab, NCT02676947).  
However, as different clinical groups, sexes and individuals are likely to have different 
drivers of disease, molecular phenotyping of patients with a precision medicine 
approach, akin to that used in cancer, may be required to identify patients most likely to 
respond to specific treatments. For example, in the context of reduced BMPR-II 
signaling (Figure 1), an individual with high SMURF1 protein expression or activity may 
respond better to a SMURF1 inhibitor rather than a treatment aiming to augment 
BMPR-II expression. To open the door for precision medicine, we need to integrate 
complex mutli-µRPLFGDWDVHWVDQGJHQHUDWHDPRUHFRPSUHKHQVLYHXQGHUVWDQGLQJRIthe 
heterogeneity in disease mechanisms, a strategy that will require a strong international 
collaboration. Nonetheless, for this devastating condition characterized by relentless 
vascular remodeling, the emerging opportunities described above provide hope of novel 
anti-remodeling treatments that will significantly improve patient outcomes in PAH.  
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TABLE 1. Clinical Classification of Pulmonary Hypertension. 
 
WHO 
group 
Classification Hemodynamics Sub-classification 
1 Pulmonary arterial 
hypertension 
Pre-capillary  
P3$3PP+J 
3$:3PP+J 
 
 
 
Idiopathic  
Heritable  
Drugs and toxins induced  
Associated with:  
   Connective tissue disease 
   HIV infection 
   Portal hypertension  
   Congenital heart disease 
   Schistosomiasis 
 
¶ PVOD and/or PCH Pre-capillary   
2 Pulmonary hypertension 
due to left heart disease 
Post-capillary 
P3$3PP+J 
PAWP >15 mmHg 
Systolic dysfunction 
Diastolic dysfunction  
Valvular disease 
Outflow/inflow tract obstruction 
Congenital cardiomyopathies 
3 Pulmonary hypertension 
due to lung disease 
and/or hypoxia  
Pre-capillary 
 
 
 
Chronic obstructive pulmonary disease  
Interstitial lung disease  
Sleep-disordered breathing  
Alveolar hypoventilation 
Chronic exposure to high altitude 
Developmental lung diseases  
4 Chronic thromboembolic 
pulmonary hypertension 
Pre-capillary Thromboembolic disease  
 
5 Pulmonary hypertension 
with unclear multifactorial 
mechanisms 
Pre-capillary or 
combined pre- 
and post-capillary   
Hematological disorders e.g. Splenectomy 
   Chronic hemolytic anemia 
   Myeloproliferative disorders 
Systemic disorders e.g. Sarcoidosis 
   Pulmonary histiocytosis 
Metabolic disorders e.g.   
   Glycogen storage disease 
   Gaucher¶V disease 
Others e.g. Tumors  
   Chronic renal failure  
WHO, World Health Organization; mPAP, mean pulmonary artery pressure; PAWP, 
pulmonary artery wedge pressure; PVOD, pulmonary veno-occlusive disease; PCH, 
pulmonary capillary hemangiomatosis. 
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Table 2. Therapeutic Manipulation of microRNAs in Animal Models. 
microRNA Target Evidence from miR-based therapies in animal models Ref 
miR-17 p21 Intravenous anti-miR-17 treatment reduced RVSP and remodeling 
in hypoxic mouse and MCT rat models.  
[84] 
miR-20a SMAD5 Prophylactic intraperitoneal injections of anti-miR-20a prevented 
RVH and remodeling in hypoxic mouse model. 
[85] 
miR-21 BMPR2, 
WWP1 
Intratracheal anti-miR-21 (prophylactic or treatment) reduced RVH 
and remodeling in hypoxic mouse model.  
[86] 
miR-26b CTGF, 
CCND1 
Intratracheal treatment with mir-26b mimic reduced remodeling in 
MCT rat model. 
[87] 
miR-27b 33$5Ȗ Intravenous anti-miR-27b treatment reduced RVSP, RVH and 
remodeling in rat MCT model.  
[88] 
miR-29 33$5Ȗ 
 
Intravenous anti-miR-29 injection attenuated RVSP and 
remodeling in Bmpr2R899X
 
(Doxycycline-induced transgene 
expression) model. 
[89] 
miR-34a PDGFRA Nebulized treatment with miR-34a mimic reversed PH in hypoxic 
rat model.  
[90] 
miR-96 5-HT1B Prophylactic intravenous administration of miR-96 mimic to 
female mice attenuated RVSP, RVH and remodeling in hypoxic 
mouse model.  
[91] 
miR-126 SPRED-1 Intravenous treatment with miR-126 mimic improved RV function 
and CO but had no significant effect on RVSP or pulmonary 
vascular remodeling in rat MCT model. 
[92] 
miR-
130/301 
33$5Ȗ 
 
Intrapharyngeal (mouse) or intraperitoneal (rat) injections of miR-
130/301 inhibitor reversed PH in SuHx mouse model and rat MCT 
model. 
[49] 
[93] 
miR-140-5p SMURF1 Nebulized miR-140-5p mimic (prophylactic or treatment) reduced 
RVSP, RVH and remodeling in rat MCT and SuHx models. 
[36] 
miR-145 KLF4 Prophylactic subcutaneous anti-miR-145 attenuated RVSP and 
remodeling in hypoxic mouse model. 
[94] 
miR-193 IGF-1R 
ALOX5/ 
12/15 
Intratracheal treatment with miR-193 mimc reduced RVSP, RVH 
and remodeling in hypoxic mouse and MCT rat models. 
[95] 
miR-199a-
5p 
SMAD3 Intravenous anti-miR-199a-5p treatment reduced RVSP and RVH 
in rat MCT model. 
[96] 
miR-204 SRC Nebulized treatment with miR-204 mimic reduced mPAP and 
remodeling in rat MCT model 
[51] 
miR-210 ISCU1/2 Intravenous anti-miR-210 (prophylactic or treatment) reduced [97] 
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5-HT1B, 5-hydroxytryptamine receptor 1B; BMPR2, bone morphogenetic protein 
receptor type 2; WWP1, WW domain containing E3 ubiquitin protein ligase 1; CTGF, 
connective tissue growth factor; CCND1, cyclin D1; FGF2, fibroblast growth factor 2; 
FGFR1, fibroblast growth factor receptor 1; IGF1R, insulin-like growth factor 1 receptor; 
ALOX5, arachidonate 5-lipoxygenase; ISCU1/2, iron-sulfur cluster assembly proteins 1 
and 2; KLF4, kruppel-like factor 4; p21, cyclin-dependent kinase inhibitor 1; PARP-1, 
poly(ADP-ribose) polymerase 1; PDGFRA, platelet-derived growth factor receptor 
alpha; 33$5Ȗ, peroxisome proliferator-activated receptor gamma; SMURF1, SMAD-
specific E3 ubiquitin-protein ligase 1; SPRED-1, sprouty related EVH1 domain 
containing 1; SRC, proto-oncogene tyrosine-protein kinase; RVSP, right ventricular 
systolic pressure; RVH, right ventricular hypertrophy; mPAP, mean pulmonary artery 
pressure; MCT, monocrotaline; SuHx, SU5416 and hypoxia; CO, cardiac output. 
  
RVSP and remodeling in SuHx mouse model.  
miR-223 PARP-1 
 
 
IGF-1R 
Nebulized treatment with miR-223 mimic reduced RVSP, RVH, 
remodeling and mortality in MCT rat model.  
 
Prophylactic adeno-associated virus transduction of miR-223 
improved cardiac output in hypoxic mouse model. 
[48] 
 
 
[98] 
miR-
424/503 
FGF2, 
FGFR1 
Intranasal delivery of lentiviral miR-424 and miR-503 reduced 
RVSP and remodeling in MCT rat model (prophylactic or 
treatment) and SuHx models (treatment).  
[52] 
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Box 1. Metabolic Reprogramming in PAH.   
Abnormalities in cellular metabolism are well described in PAH, with evidence of aerobic 
glycolysis, pentose phosphate pathway activation, mitochondrial dysfunction, altered 
fatty acid metabolism and insulin resistance in disease [99] (and reviewed in [100, 101]). 
Mitochondrial hyperpolarization [102] and the shift towards aerobic glycolysis (or 
Warburg effect [103]) has highlighted parallels between the biology of pulmonary artery 
smooth muscle cells (PASMCs) from PAH patients and cancer cells [100]. Recent work 
has increased our understanding of potential mechanisms behind these metabolic 
phenotypes.  
One study found evidence implicating the mitochondrial de-acetylase Sirtuin 3 in PAH 
[104]. PASMCs deficient in SIRT3, had reduced mitochondrial respiration and increased 
membrane potential (suppressing mitochondrial-induced apoptosis) [104]. These cells 
also displayed activation of nuclear factor of activated T cells (NFAT), signal transducer 
and activator of transcription 3 (STAT3) and hypoxia inducible factor-1alpha (HIF-1D), 
all key transcription factors linked to PAH pathogenesis [105-107]. As an upstream 
regulator of mitochondrial function linking to several key pro-proliferative and anti-
apoptotic pathways, SIRT3 may therefore constitute a promising therapeutic target. 
Interestingly, a polymorphism associated with reduced SIRT3 function was over-
represented in 49 IPAH patients [104]. However, this finding requires replication in other 
patient cohorts and the same SNP was not identified in a genome-wide association 
study [45]. While this study implies that metabolic abnormalities predate the 
development of PAH, other work has linked changes in vascular stiffness, a 
consequence of extracellular matrix (ECM) remodeling, with metabolism. Another study 
found activation of mechanosensitive transcriptional coactivators YAP (Yes-associated 
protein 1) and TAZ (transcriptional coactivator with PDZ-binding motif) in diseased 
human tissue and animal models of PH, promoting a feedback loop of ECM stiffening 
[93]. YAP/TAZ activation also reprogrammed metabolism in PAECs and PASMCs in 
vitro enhancing glycolysis and glutaminolysis, key processes in the maintenance of pro-
proliferative cell phenotypes [49].  
Beyond the pulmonary vasculature, the failure of the right ventricle (RV) to adapt and 
sustain its function in the face of rising pulmonary vascular resistance may also occur 
due to metabolic dysfunction. Using human RV tissue obtained at autopsy, direct 
evidence has been provided of a failure of long-chain fatty acid oxidation in myocardial 
cells, preventing subsequent utilization by the mitochondria. Consequent accumulation 
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of fatty acids was associated with evidence of elevated ceramide, a marker of 
lipotoxicity [108]. Visualization of lipid accumulation in the RV myocardium was also 
evident using magnetic resonance spectroscopy on living patients implying this process 
is not simply an end-stage observation [108].    
 
Box 2. DNA Damage in PAH. 
The hypothesis that DNA damage may lead to somatic mutations triggering changes in 
cell phenotype in PAH is not new with descriptions of clonal endothelial cell expansion 
in plexiform lesions and chromosomal abnormalities in explanted lung tissue [109, 110]. 
However, recent evidence reporting increased susceptibility to DNA damage [111] and 
impaired DNA repair mechanisms [48, 112] highlight the importance of these processes 
in PAH and potentially provide insight into how apoptosis-susceptible, apoptosis-
resistant and hyperproliferative cell phenotypes arise with pulmonary vascular 
remodeling.   
Significantly more DNA damage was observed in pulmonary artery endothelial cells 
from PAH patients compared to controls, but higher levels of damage were also 
demonstrated in peripheral blood mononuclear cells (PBMCs) implying that the damage 
is not confined to pulmonary vascular tissues [111]. Intriguingly a similar degree of 
damage was observed in PBMCs from the unaffected relatives of PAH patients and 
these cells showed higher sensitivity to mutagens [111]. These findings suggest that 
damage precedes the development of disease and may be determined by currently 
unknown genetic factors.  
DNA damage response mechanisms are also dysregulated in PAH. In PASMCs, excess 
damage was associated with poly(ADP-ribose) polymerase-1 (PARP-1) activation, 
promoting survival and proliferation [113].  Inhibiting PARP-1 pharmacologically or with 
the micro-RNA, miR-223, restored PASMC susceptibility to apoptosis, reduced 
proliferation and reversed established PH in experimental models [48, 113].   A further 
gene implicated in DNA repair, the breast cancer 1 (BRCA1) gene, was downregulated 
in PAECs isolated from patients with PAH and associated with increased apoptosis 
susceptibility [112].  Interestingly, BRCA1 binds to the BMPR2 promoter and also has a 
SMAD binding element in its own promoter suggesting potential interaction with the 
BMPR-II pathway that could lead to a cycle of negative regulation and thus endothelial 
dysfunction in PAH [112]. 
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Box 3. The COLQLFLDQ¶V&orner 
Reversal of aberrant pulmonary vascular remodeling in pulmonary hypertension 
remains a holy grail in the field. While currently available drugs have improved survival, 
these treatments predominantly target pulmonary vasoconstriction and are not 
specifically designed to modify molecular abnormalities associated with remodeling.  
 
Defective BMPR-II signaling, whether through genetic mutation or suppression of the 
pathway by non-genetic factors, is an important contributor to IPAH development. 
Strategies to enhance BMPR-II signaling represent important and novel therapeutic 
opportunities to dampen or reverse pulmonary vascular remodeling.   
 
An understanding of the mechanisms underpinning metabolic and inflammatory 
abnormalities in PAH has increased over recent years and has strengthened efforts to 
modify these abnormalities with drug treatments including small molecules targeting 
mitochondrial enzymes (e.g. dichloroacetate) and biologic agents targeting pro-
inflammatory cytokines (e.g. tocilizumab).    
 
Oxygen-sensing pathways are heavily implicated in PAH pathogenesis. Drugs that 
activate these pathways may be used long term in renal anemia, and the development 
of PAH as a potential complication should be considered.  
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Glossary  
 
Anastrazole, a drug use to reduce conversion of androgens to estrogens. 
 
Angioproliferative plexiform lesions are a disorganized growth of endothelial cells 
characteristic of PAH. Other histological changes include thickening of intimal and 
medial layers, muscularization of distal pulmonary arteries and vascular occlusion. 
 
Bone morphogenetic proteins are members of the TGF-ȕVXSHUIDPLO\ and are known 
to regulate embryonic patterning and organogenesis. BMPs also have a wide range of 
roles as endocrine mediators of cardiovascular, metabolic and hematopoietic functions.  
 
Blood outgrowth endothelial cells are cultured from human peripheral blood samples. 
These cells develop a typical cobblestone morphology characteristic of endothelial cell 
monolayers and express mature endothelial cell surface markers.  
 
Chuvash polycythemia is an autosomal recessive form of familial erythrocytosis 
endemic to Chuvashia that is cause by a mutation in the VHL gene. 
 
Dichloroacetate (DCA) is a pyruvate dehydrogenase kinase inhibitor that inhibits 
glycolysis (typically enhanced in PAH tissue and the right ventricle) and promotes 
oxidative phosphorylation.  
 
DNA damage. DNA is vulnerable to damage from multiple endogenous and exogenous 
insults including oxidative stress, radiation and inflammation. While multiple repair 
pathways exist, errors can occur during repair leading to sequence alterations, deletions 
and translocations. 
 
Endothelial dysfunction describes an imbalance of vasoactive mediators released 
from the pulmonary vascular endothelium resulting in vasoconstriction and failure to 
suppress smooth muscle cell proliferation. 
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Endothelial-to-mesenchymal transition is a process by which endothelial cells 
acquire a mesenchymal phenotype in association with expression of smooth muscle cell 
histological markers and genes. 
 
Forkhead box O1 (FoxO1) belongs to the forkhead family of transcription factors and 
regulates a wide variety of genes involved in metabolism, inflammation and cell division. 
 
HIF-1D and HIF-2D. Hypoxia-inducible factor (HIF) consists of a beta subunit and one of 
3 known alpha subunits. HIF-1D and HIF-2D regulate overlapping sets of target genes, 
many of which are involved in cellular adaptation to hypoxia.   
 
High Mobility Group AT-hook 1 (HMGA1) is an architectural factor that binds to DNA 
and alters the chromatin structure, thereby regulating transcriptional activity of a wide 
variety of genes.  
 
Hypoxia-induced pulmonary hypertension. Exposure to ambient hypoxia induces 
pulmonary vascular remodelling in humans and many other species and is a common 
experimental method of inducing PH in rodents. Hypoxic exposure for 2 weeks 
produces a reversible form of PH in mice. 
 
ID proteins are targets of BMP-SMAD signaling. They prevent basic helix-loop-helix 
(bHLH) domain-containing transcription factors from binding to DNA via their own bHLH 
domain. 
 
Idiopathic PAH was previously termed primary pulmonary hypertension and describes 
pre-capillary disease in the absence of conditions known to associate with the 
development of PAH or a family history of the disease. 
 
Mitochondrial-induced apoptosis. Mitochondrial membrane permeability is an 
important regulator of apoptosis and factors inducing mitochondrial dysfunction, loss of 
membrane potential and mitochondrial DNA damage can initiate this pathway.   
 
Mixed venous hypoxemia refers to a relative reduction in the oxygen content of mixed 
venous blood with low levels indicating more severe disease in PAH. 
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Monocrotaline-induced PH. Monocrotaline is a toxic plant alkaloid that induces PAH in 
rats over 2-3 weeks following injection, alongside an inflammatory response. 
 
Paclitaxel is a chemotherapeutic agent that promotes microtubule stability and 
suppresses tumor cell proliferation.     
 
Peroxisome proliferator±activated receptor-J is a transcription factor with 
downstream targets involved in glucose homeostasis and vascular remodeling. 
 
Poly [ADP-ribose] polymerase 1 (PARP-1) is an enzyme involved in the repair of 
single-stranded DNA breaks. 
 
Prolyl hydroxylase domain-containing enzymes (PHDs) are oxygen sensitive 2-
oxogluatarate dependent enzymes responsible for the hydroxylation and subsequent 
degradation of hypoxia-inducible factor alpha subunits. 
 
Pre-capillary pulmonary hypertension is an elevation mean pulmonary arterial 
pressure (greater than 25 mmHg at rest) associated with a significant increase in 
pulmonary vascular resistance (greater than 3 Wood units) and in the absence of an 
elevated pulmonary artery wedge pressure (i.e. less than or equal to 15 mmHg). Post-
capillary pulmonary hypertension is characterized by an elevated wedge pressure. 
 
Proliferative vasculopathy. In pulmonary hypertension, small pulmonary arteries 
remodel through an imbalance of proliferation and apoptosis. All layers of the vessel are 
affected with key changes comprising intimal hyperplasia, medial hypertrophy and 
adventitial fibrosis.  
 
Pulmonary arterial hypertension encompasses a group of conditions with a common 
hemodynamic phenotype of increased pulmonary arterial pressure and elevated 
pulmonary vascular resistance. Clinically the condition is characterized by progressive 
breathlessness, fatigue, syncope, right heart failure and premature death.  
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Pulmonary capillary hemangiomatosis is a rare cause of pulmonary hypertension, 
distinct from IPAH, and due to alveolar capillary proliferation. 
 
Pulmonary vasoconstriction matches ventilation and perfusion in healthy lungs, but 
PAH is characterized by sustained and severe vasoconstriction that contributes to the 
abnormal hemodynamic profile. 
 
Pulmonary veno-occlusive disease occurs due to remodeling and occlusion of the 
pulmonary veins and venules and leads to severe and progressive pulmonary 
hypertension.  
 
Rat models of pulmonary hypertension include the monocrotaline (MCT) and 
SUGEN/hypoxia (SuHx) models. SUGEN drug 5416, or SU5416, is VEGF receptor 
kinase inhibitor that induces endothelial cell apoptosis and, in combination with ambient 
hypoxia (10% oxygen), PAH develops over a 3-week period, with pulmonary vascular 
remodeling that resembles human pathology progressing over the proceeding 3-8 
weeks. 
 
Renal anemia occurs in the context of chronic kidney disease and is often treated by 
administration of erythropoietin (EPO).  EPO is a HIF target gene and therefore 
inhibitors of PHD enzymes, that regulate HIF degradation, are in clinical trials to treat 
renal anemia.    
 
Right ventricular systolic pressure (RVSP) is often reported in animal studies as it is 
not possible to advance the right heart catheter into the pulmonary artery to measure 
pulmonary arterial pressure. 
 
SLC39A12 is the gene that encodes the zinc transporter, ZIP12. 
 
SMAD proteins are a family of structurally related signaling proteins involved in BMP 
signaling.  
 
Tacrolimus, or FK506, is a calcineurin inhibitor that is commonly used as an 
immunosuppressant following transplantation. 
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Tocilizumab is an anti-IL-6 antibody currently used in rheumatoid arthritis. 
 
TopBP1 is the gene that encodes DNA topoisomerase 2-binding protein 1, a protein 
involved in DNA replication and repair. 
 
Thromboembolic disease is an important cause of pulmonary hypertension that 
results from failure of thrombus resolution within the pulmonary circulation. Often 
patients will have a history of acute pulmonary embolism. 
 
von-Hippel Lindau protein forms part of a ubiquitin ligase complex which ubiquitinates 
hydroxylated HIF-ĮVXEXQLWVPDUNLQJWKHPIRUSURWHDVRPDOGHVWUXFWLRQ 
 
Whole exome sequencing is a strategy used to find variants in the coding region of 
genes. 
 
YAP/TAZ are transcription factors in the Hippo signaling pathway and have roles in the 
regulation of cell proliferation, apoptosis and metabolism.  
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Figure Legends 
Figure 1 ± BMPR-II Dysfunction in PAH and Proposed Therapeutic Intervention 
Heterozygous gene mutations in families identified BMPR2, and therefore dysfunctional 
BMPR-II signaling, as crucial factor in the pathogenesis of PAH. Although the proportion 
of patients with PAH who harbor mutations is small, accumulating evidence points to 
reduced BMPR-II expression via a variety of mechanisms as a common molecular 
occurrence in PAH. This has led to a number of recent studies focused on identifying 
potential therapies that can augment BMPR-II signaling with the aim of identifying 
putative treatments. 1) Activation of BMPR2 gene expression using Paclitaxel via the 
activation of the transcription factor FoxO1. 2) Direct amplification of BMPR-II signaling 
in endothelial cells via administration of the endothelial selective ligand BMP9. 3) 
Tacrolimus (FK506) was demonstrated in a high throughput screen to active 
downstream BMPR-II regulated genes. Treatment with FK506 prevented the 
development of PAH in mice with endothelial deletion of Bmpr2 and reversed 
established PAH in two rat models. 4) SMURF1, a ubiquitin ligase that targets the BMP 
receptors and downstream SMAD intracellular signaling proteins, upregulated in PAH. 
Nebulized administration of miR-140-5p, shown to target and repress SMURF1, 
attenuated PAH in rat models suggesting SMURF1 inhibitors may be a potential therapy 
to restore BMPR-II signaling and treat PAH. Inhibition of the lysosomal degradation of 
BMPR-II by chloroquine (or hydroxychloroquine) also restores BMPR-II signaling in vitro 
and in preclinical models.  BMPR2, type 2 bone morphogenetic protein receptor; BMP, 
bone morphogenetic protein; FKBP12, 12-kDa FK506 binding protein; SMAD, mothers 
against decapentaplegic homologs; SMURF1, SMAD-specific E3 ubiquitin-protein ligase 
1; BRE, BMP response element. 
 
Figure 2 ± Pulmonary Vascular Remodeling and PAH Pathogenesis 
Although the exact trigger for the development of PAH is unclear there are a number of 
known risk factors and drivers of disease pathogenesis. These include host factors, 
including gene mutations such as in BMPR2, and gene variants in other pathways, and 
gender. Other acquired factors such as somatic mutations, DNA damage, exposure to 
hypoxia or drugs and toxin are also known important disease modifiers. Injury to a 
healthy vessel (left image), particularly early endothelial cell viability and loss of barrier 
integrity, is commonly thought to be the earliest manifestation of disease with alterations 
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in local shear stress and infection likely confounding factors. At a cellular level (center 
image) the most common downstream molecular consequences in IPAH are altered 
signaling through the BMP/TGF beta signaling pathways, altered miRNA expression, 
release of growth factors such as PDGF and cytokines such as IL-6 perhaps driving 
mitochondrial dysfunction and metabolic changes related to glycolysis.  As a 
consequence of this perturbed signaling there is an increase in endothelial cell 
dysfunction and increased apoptosis eventually resulting in the emergence of an 
apoptotic resistant, pro-angiogenic endothelial cells. Increased proliferation of smooth 
muscle cells and adventitial fibroblasts drives both inward and outward vascular 
remodeling, assisted by altered extracellular matrix breakdown and deposition. In 
combination with the sustained pulmonary vascoconstriction also seen in PAH, these 
progressive processes drive the pulmonary vascular remodeling in resistance 
pulmonary arteries and generates the concentric and plexiform lesions characteristic of 
PAH (right image). Largely unchecked this pulmonary vascular remodeling increases 
pulmonary vascular resistance and right ventricular afterload, eventually leading to right 
heart failure and death. BMP, bone morphogenetic protein; TGF, transforming growth 
factor; EC, endothelial cell; SMC, smooth muscle cell; ECM, extracellular matrix; RV, 
right ventricle; PDGF, platelet derived growth factor. 
 
 
 
 
